Hypertensive left ventricular hypertrophy: Pathophysiological and clinical issues

Blood Pressure

Volumn 10, Issue 5-6, 2001, Pages 288-298

  Agabiti Rosei, Enrico ^a   Muiesan, Maria Lorenza ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ALPHA ADRENERGIC RECEPTOR; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANCER GROWTH FACTOR; CAPTOPRIL; CLONIDINE; COLLAGENASE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INSULIN; METALLOPROTEINASE; NIFEDIPINE; NORADRENALIN; PRAZOSIN; PROTEIN KINASE; RENIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADRENERGIC SYSTEM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HEREDITY; HUMAN; HYPERTENSION; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; RISK FACTOR; ELECTROCARDIOGRAPHY;

CARDIOVASCULAR DISEASES; ELECTROCARDIOGRAPHY; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR;

EID: 0035527569     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370501753400593     Document Type: Review

References (71)

1. Risk mechanisms in hypertensive heart disease
2. Relationship of 24 hour blood pressure mean and variability on severity of target organ damage in hypertension
3. Circadian blood pressure change and left ventricular hypertrophy in essential hypertension
4. Relationship between initial cardiovascular structural changes and daytime and nighttime blood pressure monitoring
5. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults
6. Prognostic implications of the compensatory nature of left ventricular mass in arterial hypertension
7. Cardiopulmonary reflex before and after regression of left ventricular hypertrophy in essential hypertension
8. The effect of loading and unloading cardiopulmonary receptors on atrial natriuretic peptide in hypertensive patients with and without left ventricular hypertrophy
9. Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy
10. Impaired response of the hypertrophied left ventricle to beta adrenergic stimulation in hypertensive patients
11. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension
12. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects
13. Abnormalities of the extracellular degradation of collagen type I in essential hypertension
14. Increased serum concentration of procollagen peptides in essential hypertension
15. Matrix metalloproteinases and their inhibitors in connettive tissue remodelling
16. Relations between cardiac and vascular structure in patients with primary and secondary hypertension
17. Remodeling of the left ventricle in primari aldosteronism due to Conn's adenoma
18. Circulating Insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension
19. Heritability of left ventricular mass
20. Association between a deletion polimorphysm of the angiotensin converting enzyme gene and left ventricular hypertrophy
21. The deletion/insertion polimorphysm of the angiotensin - Converting enzyme and cardiovascular - Renal risk
22. Aldosterone synthase gene polimorphysm and cardiovascular phenotypes in a general population
23. Evaluation of cardiac and vascular structure and function by echocardiography and other non-invasive techniques
24. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men
25. Clinical impact of different modeling of echocardiographic left ventricular mass
26. Various ways of calculating echocardiographic left ventricular mass and their relative prognostic values
27. Reliability and limitations of measurement of echocardiographic left ventricular mass for single patients stratification and follow-up: The RES study
28. Reliability of echocardiographic assessment of left ventricular structure and function. The PRESERVE study
29. Effect of growth on variability of left ventricular mass: Assessment of allometric signals in adults and children and of their capacity to predict cardiovascular risk
30. Patterns of left ventricular hypertrophy and geometric remodelling in arterial hypertension
31. Adverse prognostic significance of concentric remodelling of the left ventricle in hypertensive patients with normal left ventricular mass
32. Left ventricular chamber filling and midwall fiber lengthening in patients with left ventricular hypertrophy: Overestimation of fiber velocities by conventional midwaii measurements
33. Assessment of left ventricular function by midwali fractional shortening-endsystolic stress relation in human hypertension
34. Midwall left ventricolar mechanics. An independent predictor of cardiovascular risk in arterial hypertension
35. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline LV mass or systolic performance. A ten years follow-up
36. Hypertension and Diastolic function
37. Left ventricular systolic function as related to impaired diastolic filling in essential hypertension
38. Ultrasonic videodensitometric analysis of two different models of left ventricular hypertrophy: Athlete's heart and hypertension
39. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: Endomyocardial biopsy versus ultrasonic tissue characterization
40. 1999 World health Organization - International Society of Hypertension Guidelines for the management of Hypertension
41. Prognostic implications of left ventricular hypertrophy
42. Upward shift of the lower range of coronary autoregulation in hypertensive patients with hypertrophy of the left ventricle
43. Cardiac hypertrophy in hypertension: Repolarization abnormalities elicited by rapid lowering of pressure
44. Effects of angiotensin blockade on coronary circulation and coronary reserve
45. Dipyridamole echocardiography stress testing in hypertensive patients. Targets and tools
46. Mechanisms of coronary flow reserve impairment in human hypertension. An integrated approach by transthoracic and transesophageal echocardiography
47. Cardiac rythm in hypertension assessed through 24 hours ambulatory electrocardiographic monitoring. Effect of load manipulation with atenolol, verapamil and nifedipine
48. Effect of changes in blood pressure and left ventricular mass induced by antihypertensive treatment on ventricular arrhythmias in essential hypertension
49. Treatment of Mild Hypertension Study. Final results
50. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy
51. The smoothness index: A new reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension
52. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
53. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy
54. Reversibility of left ventricular hypertrophy by antihypertensive drug
55. Reversal of left ventricular hypertrophy in essential hypertension: A meta-analysis of randomized double blind studies
56. Reversibility of left ventricular hypertrophy and mulfunction by antihypertensive treatment
57. ACE-inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular hypertrophy in hypertensionresults of the RACE (ramipril cardioprotective evaluation study)
58. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension comparison of six antihypertensive agents: The Department of Veterans Affairs Cooperative Study Group on Antihypertensive agents
59. Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: A result of a multicenter trial
60. Effects of once daily angiotensin-converting enzyme inhibition and calcium channel blockade - Based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The enalapril study evaluating regression of ventricular enlargement (PRESERVE) trial
61. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: The L.I.V.E. Study
62. Influence of the Angiotensin II antagonist Valsartan on lft ventricular hypertrophy in patients with essential hypertension
63. Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE Study
64. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease
65. Collagen matrix synthesis and degradation in the development and regression of left ventricular hypertrophy
66. Chronic AT1 blockade stimulates extracellular collagen type 1 degradation and reverses myocardial fibrosis in spontaneously hypertensive rats
67. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
68. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin converting enzyme inhibitor, ramipril
69. Changes in left ventricular mass predict risk in essential hypertension
70. Association of change in left ventricular mass with prognosis during longterm antihypertensive treatment
71. Prognostic significance of serial changes in left ventricular mass in essential hypertension